Article
Predictive model of bosentan-induced liver toxicity in Japanese patients with pulmonary arterial hypertension.
Canadian journal of physiology and pharmacology - 1 Sept 2020
Yorifuji Kennosuke, Uemura Yuko, Horibata Shinji, Tsuji Goh, Suzuki Yoko, Nakayama Kazuhiko, Hatae Takashi, Kumagai Shunichi, Emoto Noriaki
Abstract excerpt
Bosentan, an endothelin receptor antagonist, has been widely used as a first-line medication for the treatment of pulmonary arterial hypertension (PAH). It has been shown to improve symptoms of hypertension, exercise capacity, and hemodynamics and prolong time to clinical worsening. However, liver dysfunction is a major side effect of bosentan treatment that could hamper the optimal management of patients with...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
